Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved over the years, and we are now in an era of combination therapy strategies employing immune checkpoint blockade and anti-angiogenesis targeted therapy. Since 2018, we have gained regulatory approval for four distinct c...
Main Authors: | Kevin K. Zarrabi, Oladimeji Lanade, Daniel M. Geynisman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/19/4607 |
Similar Items
-
Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
by: Ameish Govindarajan, et al.
Published: (2022-04-01) -
Contemporary treatment of metastatic renal cell carcinoma
by: Igor Stukalin, et al.
Published: (2016-07-01) -
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
by: Kevin Zarrabi, et al.
Published: (2021-07-01) -
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
by: Adam M. Kase, et al.
Published: (2023-01-01) -
Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy
by: Hanzhi Dong, et al.
Published: (2023-10-01)